Kimia Biosciences Strengthens Board and Management Team

Kimia Biosciences Limited has announced significant leadership changes, appointing two new Non-Executive Independent Directors, Avinash Prabhat and Reema Goyal, effective April 4, 2026. These appointments are designed to enhance the company's board oversight and governance expertise.

The company also noted the cessation of Jagdeep Dhawan as Independent Director on March 28, 2026.

In addition to the directorial appointments, Abhishek Kumar Pandey has been named the new Company Secretary & Compliance Officer, also effective April 4, 2026. This follows the resignation of Pallavi Garg from the same role on April 3, 2026.

These personnel changes aim to strengthen the board's guidance and bring fresh perspectives to the company's strategic direction. The continuity in the critical Company Secretary role ensures ongoing compliance management for the Active Pharmaceutical Ingredients (API) and intermediates manufacturer.

Kimia Biosciences has experienced various leadership realignments in recent months. However, shareholders demonstrated confidence in the existing top leadership by overwhelmingly re-appointing Mr. Sameer Goel as Managing Director for a five-year term in March 2026.

The company has faced regulatory scrutiny, particularly regarding environmental compliance and tax filings. In the fiscal year 2022-2023, the Haryana State Pollution Control Board imposed a penalty of approximately ₹1.048 Crores for non-compliance. The company also received significant demands from the GST Department in Andhra Pradesh related to non-filing of returns, amounting to ₹1.22 Crores and ₹3.6 Crores for different periods, for which appeals are reportedly being pursued.

Operating in the competitive pharmaceutical API and intermediates manufacturing sector, Kimia Biosciences competes with peers such as Brooks Laboratories, Laurus Labs, and Divi's Laboratories. While its market capitalization is comparable to some smaller competitors, its financial stability, as indicated by the Altman Z-score, is noted as lower compared to its peers.

For the financial year ending March 31, 2025, Kimia Biosciences reported revenues of ₹120 Crore. As of February 2026, the company's market capitalization stood at ₹123 Crores.

Key areas for investors to monitor include shareholder approval for the new directors. The company's ongoing efforts to bolster its compliance and regulatory adherence, along with its ability to manage outstanding GST demands, will also be important indicators of future performance and strategic direction.